Vascular Closure Devices Market is projected to reach USD 2.2 Billion by 2036 at a 3.4% CAGR from 2026.

NEWARK, DE -The global vascular closure devices market stood at USD 1.6 billion in 2026 and is forecast to expand to USD 2.2 billion by 2036, reflecting a steady CAGR of 3.4% over the decade. This growth is driven by the increasing volume of catheter-based interventional procedures, the clinical transition from manual compression to active closure techniques for both arterial and venous access sites, and the rising adoption in structural heart and electrophysiology procedures that demand reliable large-bore vascular access management. As healthcare providers prioritize faster hemostasis, reduced time to ambulation, and improved patient outcomes, the vascular closure devices market continues to evolve toward more versatile, multi-access solutions.

Read Full Report:https://www.futuremarketinsights.com/reports/vascular-closure-devices-market

Market snapshot: global market 2026 - 2036

Market size 2026? USD 1.6 billion
Market size 2036? USD 2.2 billion
CAGR? 3.4%
Leading product segment(s) and shares - The vascular closure devices market encompasses suture-mediated, collagen-based, extravascular sealant (PEG), clip-based, and compression-assisted closure systems; specific segment shares for leading categories are not quantified beyond the overall active vs. passive distinction, with active devices gaining traction in interventional settings.
Leading material type and share - Not explicitly segmented by material dominance in the provided data; focus remains on device types like PEG sealants in venous applications.
Leading end use and share - Hospitals and catheterization labs dominate due to high procedural volumes, though exact percentage shares are not specified; ambulatory surgical centers are expanding for outpatient procedures.
Key growth regions - China records the fastest growth, while the United States retains the largest value share.
Top companies - Teleflex (MANTA), Haemonetics (VASCADE, Vivasure), Abbott (Perclose ProGlide), Cordis (MYNX CONTROL), Terumo, with additional players including Medtronic, Johnson & Johnson, and others.

Market Momentum (YoY Path)

The vascular closure devices market is set for measured expansion through the forecast period. Starting at USD 1.6 billion in 2026, the market demonstrates consistent year-over-year progress fueled by procedural volume increases and technology adoption. Intermediate milestones include continued penetration in venous and large-bore applications around 2028-2030, with structural heart procedure acceleration supporting further gains by 2031 and 2033. By 2035, the trajectory positions the market close to its terminal value ahead of reaching USD 2.2 billion in 2036, underscoring reliable demand in interventional cardiology and electrophysiology.

Why the Market is Growing

The vascular closure devices market benefits from the rising volume of catheter-based interventional procedures globally, including percutaneous coronary interventions (PCI) exceeding 600,000 annually in the United States alone. The shift toward active closure over manual compression enables reduced time to hemostasis and earlier patient ambulation, particularly valuable in same-day discharge protocols. Expansion in structural heart and electrophysiology procedures further necessitates effective large-bore and venous access management, propelling adoption of specialized devices.

Segment Spotlight

Product Type Active vascular closure devices - including suture-mediated, collagen-based, sealant (PEG), and clip-based systems - are seeing increased preference for instant hemostasis in post-catheterization settings. These solutions reduce recovery times, complications, and support greater patient mobility compared to passive options. The market is transitioning toward multi-bore platforms addressing venous-specific and large-bore needs.

Material Type Sealant-based technologies, particularly PEG extravascular sealants, play a prominent role in venous closure applications. Devices like Cordis MYNX CONTROL Venous highlight the emphasis on effective, complication-minimizing hemostasis, aligning with broader hygiene and cleanup priorities in catheterization labs by enabling cleaner, faster access site management.

End Use Hospitals and catheterization labs represent the core end use, driven by high volumes of PCI, angioplasty, and other catheter-based procedures. The narrative centers on improving procedural efficiency, minimizing hospital stays, and reducing post-procedure bleeding risks in these high-throughput environments, with growing contributions from ambulatory surgical centers for outpatient interventions.

Drivers, Opportunities, Trends, Challenges

Drivers Key drivers include the surge in catheter-based procedures, adoption of active closure to replace manual compression, and the clinical need for reliable hemostasis in arterial, venous, and large-bore access sites. Same-day discharge protocols and structural heart program expansion further accelerate demand.

Opportunities Hybrid vascular closure systems integrating suture, collagen, and bioresorbable elements present significant potential by offering versatility, faster hemostasis, and reduced complications across varied access sizes and patient groups. Ongoing clinical trials and technological progress support broader adoption in interventional cardiology and peripheral procedures.

Trends The vascular closure devices market is shifting toward multi-access, multi-bore ecosystems featuring venous-specific platforms, large-bore structural heart solutions, and imaging-guided integration. Trends encompass venous closure expansion, large-bore portfolio building via acquisitions, and the convergence of technologies replacing traditional femoral arterial compression workflows.

Challenges High costs of advanced technologies, risks of vascular complications (hematomas, pseudo-aneurysms), stringent regulatory barriers, and uneven adoption between high-tech and low-infrastructure settings pose hurdles. Compatibility with diverse sheath sizes, training needs, and reluctance to move from manual compression remain additional barriers.

Country Growth Outlook (CAGR)

China: 6.3% (noting fastest growth from expanding catheterization lab infrastructure; source data lists 8.2% in one instance but 6.3% in country insights-using 6.3% as per detailed forecast)
India: Strong development implied, but exact CAGR not uniformly stated beyond regional momentum
Germany: 3.2%
France: Not individually quantified
UK: Not individually quantified
USA: 2.0%
Brazil: Not quantified

Competitive Landscape

The vascular closure devices market features concentrated competition among key players focused on innovation in venous, large-bore, and active closure technologies. Leading companies include Teleflex (MANTA large-bore), Haemonetics (VASCADE MVP XL and Vivasure acquisition), Abbott (Perclose ProGlide), Cordis (MYNX CONTROL Venous), Terumo (Angio-Seal), and others such as Medtronic and Johnson & Johnson. M&A activity - including Haemonetics' USD 116 million acquisition of Vivasure in January 2026 and Teleflex's agreement for Biotronik's Vascular Intervention business in February 2025 - underscores portfolio expansion into emerging segments.

Scope of the Report

Quantitative units: USD Million (market value)
Segmentation: Product type (suture-mediated, collagen-based, sealant (PEG), clip-based, compression-assisted); access site (femoral arterial, femoral venous, radial, large-bore); end user (hospitals, catheterization labs, ambulatory surgical centers)
Regions: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Countries: United States, Germany, China, India, Japan (with select insights), among others
Key companies profiled: Teleflex, Haemonetics, Abbott, Cordis, Terumo, Zylox-Tonbridge

Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1809

Get Access of Report Sample:https://www.futuremarketinsights.com/reports/sample/rep-gb-1809

FAQ

What is the growth outlook for the vascular closure devices market as per Future Market Insights projection? Future Market Insights projects the vascular closure devices market to expand at a CAGR of 3.4% from 2026 to 2036, increasing from USD 1.6 billion in 2026 to USD 2.2 billion by 2036.

How do FMI analysts perceive the vascular closure devices market to evolve? FMI analysts see the market evolving toward multi-bore closure ecosystems, where venous-specific, large-bore structural heart, and imaging-guided platforms increasingly replace standard femoral arterial compression workflows.

Which country holds the largest share in the global vascular closure devices market? The United States holds a significant share by value, supported by over 600,000 annual PCI procedures, same-day discharge adoption, and concentration of leading company operations.

How large will the vascular closure devices market be by 2036? The global vascular closure devices market is projected to reach USD 2.2 billion by 2036.

What is the definition of the vascular closure devices market? The vascular closure devices market includes suture-mediated, collagen-based, sealant-based (PEG), clip-based, and compression-assisted closure systems used to achieve hemostasis at arterial and venous catheter access sites in hospitals and catheterization laboratories.

What are globally unique trends shaping the vascular closure devices market? Globally unique trends include large-bore structural heart closure expansion, venous-specific PEG sealant closure, and imaging-guided closure integration.

Explore More Related Studies Published by FMI Research:

Lung Cancer Surgery Market: https://www.futuremarketinsights.com/reports/lung-cancer-surgery-market

Beadlets Capsule Market: https://www.futuremarketinsights.com/reports/beadlets-capsule-market

Demand for Antibody-mediated Rejection Prevention in USA: https://www.futuremarketinsights.com/reports/united-states-antibody-mediated-rejection-prevention-market

Demand for Anti-biofilm Wound Dressing in USA: https://www.futuremarketinsights.com/reports/united-states-anti-biofilm-wound-dressing-market

DKK-1 Biomarker Market: https://www.futuremarketinsights.com/reports/dkk-1-biomarker-market

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com

Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

This release was published on openPR.